In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
The Nordic Microscopy Society meeting in Lyngby Denmark offers several opportunities to meet with us and to hear about the latest HoloMonitor news.
Notice to the shareholders in Phase Holographic Imaging AB (publ), 556542-7811, to attend an Extraordinary General Meeting on Monday June 18 at 06.00 PM (18.00) at PHI’s office, Scheelevägen 22, Lund.
Decision on rights issue for continued growth, establishment of sales organization and commercial break-through
The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.
PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter.
QIMR Berghofer Medical Research Institute in Brisbane and PHI have entered an evaluation agreement to explore the use of live cell time-lapse cytometry based on quantitative phase microscopy to determine the impact of hypoxic microenvironment on cellular motility and metastatic potential in solid cancers.
Today Phase Holographic Imaging (PHI) launches a new website. The new website has been created to comprehensively provide extensive product information, as well as an introduction to the range of cell biology applications supported by the HoloMonitor® system.
University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence
University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.
Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.